Seegene Announces Submission to U.S. FDA for Emergency Use Authorization of Its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay
Published on: BUSINESS WIRE Real-time test differentiates influenza A & B, RSV and COVID-19 SEOUL, South Korea (March 1, 2021)— Seegene Inc., (KQ096530), a biotechnology
Seegene’s Latest COVID-19 Test Can Simultaneously Target 4 Genes of SARS-CoV-2 and Recognize Multiple Virus Variants
Published on: PR Newswire – Seegene’s new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 min– Seegene’s proprietary high multiplex
Seegene’s saliva test for COVID-19 is just as effective as NPS test
Published on: PR Newswire A new study shows that the less-invasive saliva test for COVID-19 gives just as accurate results as those of the nasopharyngeal
Seegene develops world first COVID-19 variant test capable of identifying origins of virus variants
Published on: PR Newswire SEEGENE LAUNCHES FIRST MULTIPLEX TEST TO IDENTIFY COVID-19 MUTANTS THE MANUFACTURER OF COVID-19 TESTS CONTINUOUSLY FOLLOWS THE SPREAD OF THE VARIANTS
Seegene introduces a High-throughput 8-plex Test for Flu A, Flu B, RSV and COVID-19 with dual internal controls
SEOUL, South Korea, Sept. 8, 2020 /PRNewswire/ — Seegene, Inc. introduced a single tube real-time RT-PCR assay, Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, which simultaneously detects and differentiates Flu A,
Seegene’s Allplex™ 2019-nCoV Assay receives FDA Emergency Use Authorization
Published on: 매일경제 한국경제 PR Newswire 조선일보 SEOUL, Korea, Apr 22, 2020 – Seegene, Inc. announced that U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA)